TIDMHIK
RNS Number : 9338X
Hikma Pharmaceuticals Plc
28 April 2023
Hikma Pharmaceuticals PLC
Results of 2023 Annual General Meeting
LONDON, 28 April 2023 Hikma Pharmaceuticals PLC (LSE: HIK)
(NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75)
announces its Annual General Meeting ("AGM"), held at Sofitel
London St James, 6 Waterloo Place, London SW1Y 4AN and virtually on
28 April 2023 commenced at 11 am. All the proposed resolutions were
duly passed by shareholders by way of a poll. Resolutions 1 to 20
were passed as ordinary resolutions and Resolutions and 21 to 24
were passed as special resolutions.
Copies of the resolutions dealing with special business passed
at the AGM have been submitted to the FCA's Electronic Submission
System and will be available from the National Storage
Mechanism.
The total number of votes cast on the poll for each resolution
(the full text of the resolutions is detailed in the notice of the
AGM dated 16 March 2023) is set out below. The number of Ordinary
Shares in issue on 27 April 2023 was 233,821,373. There were
12,833,233 Ordinary Shares held in treasury, which are not counted
in the voting capital of the Company which, therefore, was
220,988,140.
Resolution Votes % Votes Against % Total Cast Withheld
For
1. To receive the
2022 report and
accounts 173,404,465 99.99 18,525 0.01 173,422,990 1,486,671
------------ ------- -------------- ----- ------------ ----------
2. To approve a
final dividend of
37 cents per share 174,904,572 100.00 3,407 0.00 174,907,979 1,682
------------ ------- -------------- ----- ------------ ----------
3. To re-appoint
PricewaterhouseCoopers
LLP as Auditor 173,901,259 99.43 1,004,451 0.57 174,905,710 3,951
------------ ------- -------------- ----- ------------ ----------
4. To authorise
the Audit Committee
to determine the
remuneration of
the Auditor 174,902,468 100.00 4,247 0.00 174,906,715 2,946
------------ ------- -------------- ----- ------------ ----------
5. To elect Laura
Balan as a Director
of the Company 174,560,635 99.80 345,653 0.20 174,906,288 3,373
------------ ------- -------------- ----- ------------ ----------
6. To elect Victoria
Hull as a Director 172,985,379 98.90 1,920,959 1.10 174,906,338 3,322
------------ ------- -------------- ----- ------------ ----------
7. To elect Dr
Deneen Vojta as
a Director 174,145,610 99.57 759,059 0.43 174,904,669 4,992
------------ ------- -------------- ----- ------------ ----------
8. To re-elect
Said Darwazah as
a Director 167,417,879 95.79 7,363,833 4.21 174,781,712 127,949
------------ ------- -------------- ----- ------------ ----------
9. To re-elect
Mazen Darwazah as
a Director 166,197,026 95.09 8,584,687 4.91 174,781,713 127,948
------------ ------- -------------- ----- ------------ ----------
10. To re-elect
Patrick Butler as
a Director 169,789,166 97.08 5,115,966 2.92 174,905,132 4,529
------------ ------- -------------- ----- ------------ ----------
11. To re-elect
Ali Al-Husry as
a Director 173,667,423 99.36 1,114,623 0.64 174,782,046 127,615
------------ ------- -------------- ----- ------------ ----------
12. To re-elect
John Castellani
as a Director 174,135,021 99.56 770,111 0.44 174,905,132 4,529
------------ ------- -------------- ----- ------------ ----------
13 . To re-elect
Nina Henderson as
a Director 172,945,073 98.88 1,961,390 1.12 174,906,463 3,198
------------ ------- -------------- ----- ------------ ----------
14 . To re-elect
Cynthia Flowers
as a Director 174,560,963 99.80 345,325 0.20 174,906,288 3,373
------------ ------- -------------- ----- ------------ ----------
15 . To re-elect
Douglas Hurt as
a Director 174,135,291 99.56 769,811 0.44 174,905,102 4,559
------------ ------- -------------- ----- ------------ ----------
16. To receive
and approve the
annual report on
Remuneration 169,944,824 97.16 4,959,681 2.84 174,904,505 5,145
------------ ------- -------------- ----- ------------ ----------
17. To approve
the Directors' Remuneration
Policy 171,820,411 98.24 3,085,011 1.76 174,905,422 4,239
------------ ------- -------------- ----- ------------ ----------
18. To authorise
the Directors to
allot shares and
grant rights to
subscribe for shares 169,738,766 97.05 5,168,220 2.95 174,906,986 2,674
------------ ------- -------------- ----- ------------ ----------
19. To approve
the Long-Term Incentive
Plan 2023 172,742,090 98.76 2,164,458 1.24 174,906,548 3,113
------------ ------- -------------- ----- ------------ ----------
20. To approve
the Deferred Bonus
Plan 2023 173,885,322 99.42 1,021,749 0.58 174,907,071 2,590
------------ ------- -------------- ----- ------------ ----------
21 . To authorise
the disapplication
of pre-emption rights
(General) 166,689,167 95.30 8,217,162 4.70 174,906,329 3,331
------------ ------- -------------- ----- ------------ ----------
22. To authorise
the disapplication
of pre-emption rights
(Acquisition or
Capital Investment) 159,504,839 91.19 15,401,490 8.81 174,906,329 3,331
------------ ------- -------------- ----- ------------ ----------
23. To authorise
the Company to purchase
Ordinary Shares 173,797,944 99.42 1,018,079 0.58 174,816,023 93,638
------------ ------- -------------- ----- ------------ ----------
24. To authorise
the Company to hold
general meetings
on not less than
14 clear days' notice 169,319,647 96.81 5,588,186 3.19 174,907,833 1,828
------------ ------- -------------- ----- ------------ ----------
Senior Independent Director
At the conclusion of the AGM, as reported in our 2022 Annual
Report, Patrick Butler stepped down as Senior Independent Director,
Chair of the Nomination and Governance Committee and as a member of
the Audit Committee and Remuneration Committee. Patrick Butler will
remain on the Board as a non-independent Non-Executive Director for
one further year, stepping down no later than the 2024 AGM.
Victoria Hull was appointed as Senior Independent Director and
Chair of the Nomination and Governance Committee.
Declaration of final dividend
The dividend of 37 cents per share will be paid on 5 May 2023 to
shareholders on the register on 24 March 2023. Shareholders who are
not resident in Jordan have been given the option of receiving
their dividend in Pounds Sterling. The exchange rate in respect of
this dividend will be $1.2532 to GBP1. The exchange rate for
Jordanian Dinar is fixed to the US Dollar at circa $1 to
0.71JD.
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Hussein Arkhagha
Chief Counsel and Company Secretary +44 20 7399 2670
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGSEDFLAEDSEEL
(END) Dow Jones Newswires
April 28, 2023 10:25 ET (14:25 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Hikma Pharmaceuticals (LSE:HIK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
